Company AI Risk Explorer
Loading the data…
Welcome to the Company AI Risk Explorer

This tool maps what large global companies say in public about AI risk. We reviewed public documents from roughly 200 of the world's largest companies. We coded every risk they acknowledge against the AI Risk Repository taxonomy.

Filter by company, sector, AI role, or risk. Compare what companies acknowledge against expert ratings of severity, sector vulnerability, and role responsibility.

← Back to the overview Company AI Risk Explorer

Companies × risks

AstraZeneca

AstraZeneca deploys AI across its R&D pipeline and adopts external AI platforms through partnerships (Immunai, Absci). It also develops specialised biomedical AI, including the open-source Kazu BioNLP framework presented at EMNLP and deep learning libraries for drug-related applications.

We reviewed 4 public documents from AstraZeneca and found it acknowledges 2 of 24 AI risks: discrimination and transparency & interpretability.

Sector: Agriculture, Mining, Construction and Manufacturing; Chemicals & pharmaceutical manufacturing

Roles: AI deployer; Specialized AI developer

AI risks AstraZeneca acknowledges

  • Discrimination: “AI systems can amplify biased and discriminatory decision making” (AstraZeneca Risk Supplement 2024)
  • Transparency & interpretability: “generate insights which are difficult to interpret and explain” (AstraZeneca Risk Supplement 2024)

Documents we reviewed